Furthermore, previous clinical studies have showed that a high tumour burden is a negative predictive factor for the efficacy of PD‐1/PD‐L1 inhibitor monotherapy in patients with advanced NSCLC.9, 10. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.